出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2024年1月
Carrier Screening Market – Global Forecast to 2028
キャリアスクリーニング市場 : 製品とサービス、タイプ［拡張（カスタマイズ、事前設計）］対象疾患、病状（血液、肺）、技術（DNAシークエンシング、PCR）、エンドユーザー、地域別 – 2028年までの世界予測
Carrier Screening Market by Product and Service, Type (Expanded (Customized, Predesigned) Targeted Diseases, Medical condition (Hematologic, Pulmonary), Technology (DNA Sequencing, PCR), End user, Region – Global Forecast to 2028
| ページ数 | 224 |
| 図表数 | 254 |
| 種別 | 英文調査報告書 |
| 価格 |
Report Overview
The global Carrier Screening Market is expected to reach USD 5.4 Billion by 2028 from USD 2.2 Billion in 2023, at a CAGR of 19.7% during the forecast period.
世界のキャリアスクリーニング市場は、予測期間中に19.7%のCAGRで、2023年の22億米ドルから2028年までに54億米ドルに達すると予想されています。
Market is driven by factors such as Ongoing advancements in genetic testing technologies, such as next-generation sequencing (NGS), improve the efficiency, accuracy, and cost-effectiveness of carrier screening, The increasing prevalence of genetic disorders, coupled with a greater understanding of the genetic basis of various conditions On the other hand, The demand for genetic counseling services often exceeds the available resources. A shortage of genetic counselors can hinder the delivery of comprehensive counseling to individuals undergoing carrier screening, potentially limiting the understanding and interpretation of results.
“The Neurological Conditions accounted for the second largest market share in the carrier screening market product’ s market, during the forecast period”
Based on the Medical Conditions, Carrier Screening Market is classified into Hematologic Conditions, Pulmonary Conditions, Neurological Conditions, and Others. In 2022, Neurological Conditions accounted for a sizable market share because Many neurological disorders have a genetic component. Understanding the genetic basis of conditions such as Huntington’s disease, amyotrophic lateral sclerosis (ALS), and certain forms of epilepsy can be crucial for assessing the risk of passing on these conditions to future generations. Likewise, Carrier screening for neurological conditions allows for early detection of genetic risk factors. Early identification of carriers provides an opportunity for individuals and couples to make informed reproductive decisions and consider interventions or therapies early in the planning stages.
“PCR technology segment accounted for the second largest market share”
Based on type on technology, the carrier screening market is segmented into DNA Sequencing, PCR, DNA Microarray, and Other. The PCR technology segment accounted for the second largest market share in 2022., due to its variety of applications such as PCR technology is known for its high sensitivity and specificity in amplifying and detecting specific DNA sequences. This accuracy is crucial in carrier screening to reliably identify carriers of genetic mutations associated with various disorders, likewise, PCR allows for the amplification of multiple target DNA sequences in a single reaction, a feature known as multiplexing. This capability is valuable in carrier screening,
“APAC region accounted for the third highest CAGR”
The global Carrier Screening market is divided into four regions: North America, Asia-Pacific, Europe, and Rest of the World. According to the regional analysis, the Asia-Pacific region is likely to retain a considerable market share in 2022 and the future. The Asia-Pacific market is being propelled by an rising cases of rare disease, rising in healthcare expenditure, rising in awareness about early disease diagnosis.
“Europe is estimated to register the second highest CAGR during the forecast period.”
In this report, the Carrier Screening market is segmented into four major regional segments: North America, Europe, Asia Pacific, Rest of the world. The market in Europe is projected to register the second highest growth rate during the forecast period. The growth in this market is due to Europe has a strong tradition of research and academic excellence, the rising incidence of genetic and rare diseases, government funding for research and healthcare in many European countries supports the development and adoption of advanced diagnostic technologies such as carrier screening.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 32%, Tier 2 – 44%, and Tier 3 – 24%
• By Designation: C-level – 30%, D-level – 34%, and Others – 36%
• By Region: North America – 40%, Europe – 28%, Asia Pacific – 20%, and the Rest of the World – 12%
Lits of Companies Profiled in the Report:
Invitae Corporation. (US)
Fulgent Genetics.(US)
Eurofins Scientific (Germany)
OPKO Health, Inc.(US)
Thermo Fisher Scientific Inc.(US)
Quest Diagnostics Incorporated (US)
Myriad Genetics, Inc (US)
Illumina, Inc.(US)
Natera, Inc.(Italy)
Laboratory Corporation of America Holdings.(US)
CENTOGENE N.V.(Germany)
DiaSorin S.p.A.(Italy)
BGI (China)
Otogenetics (US)
GeneTech (India)
Signature Diagnostics Inc.(US)
MedGenome (US)
Ambry Genetics.(US)
Asper Biogene (Estonia)
LifeLabs Genetics (Canada)
EasyDNA (US)
LifeCell (India)
CNC Path Lab (India)
Oxy-Gen Laboratory LLC (US)
Mitera (US)
Research Coverage:
This report studies the Carrier Screening market based on Product & Service, Type, Medical Condition, Technology, End User, and Region. The report also analyses factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total Carrier Screening market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
Market Drivers: Comprehensive information about driving factors of the markets. The report analyses the markets drivers across key geographic regions.
Market Penetration: Comprehensive information on Carrier Screening Market products offered by the top 25 players in the market. The report analyses the Carrier Screening market by Product & Service, Type, Medical Condition, Technology, End User, and Region.
Market Development: Comprehensive information about lucrative emerging markets. The report analyses the markets for various securement devices across key geographic regions.
Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the Carrier Screening market
Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the Carrier Screening market
Market Position: It will upkeep stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.
Table of Contents
1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.3 INCLUSIONS & EXCLUSIONS 32
1.4 MARKET SCOPE 33
1.4.1 MARKETS COVERED 33
1.4.2 REGIONS COVERED 33
1.4.3 YEARS CONSIDERED 34
1.4.4 CURRENCY CONSIDERED 34
1.5 STAKEHOLDERS 34
1.6 SUMMARY OF CHANGES 35
1.6.1 RECESSION IMPACT: CARRIER SCREENING MARKET 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH DATA 36
FIGURE 1 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 36
FIGURE 2 KEY SECONDARY SOURCES 38
2.1.2 PRIMARY DATA 39
FIGURE 3 PRIMARY SOURCES 39
2.1.2.1 Key data from primary sources 39
2.1.2.2 Key industry insights 40
2.1.2.3 Breakdown of primary interviews 41
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 41
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 41
2.2 MARKET ESTIMATION 41
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 42
FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 42
FIGURE 7 MARKET SIZE ESTIMATION: CARRIER SCREENING MARKET 43
2.2.2 GROWTH FORECAST 44
FIGURE 8 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS 44
FIGURE 9 TOP-DOWN APPROACH 45
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 46
FIGURE 10 DATA TRIANGULATION METHODOLOGY 46
2.4 RESEARCH LIMITATIONS 47
2.5 MARKET SHARE ANALYSIS 47
2.6 STUDY ASSUMPTIONS 47
2.7 RISK ASSESSMENT 48
TABLE 1 RISK ASSESSMENT: CARRIER SCREENING MARKET 48
2.8 IMPACT OF ECONOMIC RECESSION ON CARRIER SCREENING MARKET 49
3 EXECUTIVE SUMMARY 50
FIGURE 11 CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 50
FIGURE 12 CARRIER SCREENING MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 51
FIGURE 13 CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2023 VS. 2028 (USD MILLION) 51
FIGURE 14 CARRIER SCREENING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 52
FIGURE 15 CARRIER SCREENING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 53
FIGURE 16 CARRIER SCREENING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 53
4 PREMIUM INSIGHTS 55
4.1 CARRIER SCREENING MARKET OVERVIEW 55
FIGURE 17 GROWING PREVALENCE OF GENETIC DISORDERS TO DRIVE MARKET 55
4.2 CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2023–2028 55
FIGURE 18 PREDESIGNED PANEL TESTING SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 55
4.3 NORTH AMERICA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE AND COUNTRY, 2023 56
FIGURE 19 US AND PRODUCTS TO DOMINATE NORTH AMERICAN CARRIER SCREENING MARKET IN 2023 56
4.4 GEOGRAPHICAL GROWTH OPPORTUNITIES: CARRIER SCREENING MARKET 56
FIGURE 20 US TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS 57
FIGURE 21 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: CARRIER SCREENING MARKET 57
5.2.1 DRIVERS 58
5.2.1.1 Increasing emphasis on early disease detection and prevention 58
5.2.1.2 Growing prevalence of genetic disorders 58
5.2.1.3 High risk of chromosomal abnormalities with advancing maternal age 59
TABLE 2 GLOBAL INCIDENCE RATE OF TRISOMY 59
5.2.1.4 Increased focus on preconception and prenatal testing 59
5.2.1.5 Rising number of fertility clinics and IVF centers 60
5.2.1.6 Declining rate of fertility 60
TABLE 3 FERTILITY RATE (BIRTHS PER WOMAN), BY COUNTRY 61
5.2.2 RESTRAINTS 61
5.2.2.1 Ethical concerns in preconception genetic carrier screening 61
5.2.2.2 High cost of carrier screening 62
5.2.3 OPPORTUNITIES 62
5.2.3.1 Increased awareness about reproductive health in emerging economies 62
FIGURE 22 HEALTHCARE EXPENDITURE PER CAPITA IN BRICS, 2012–2020 63
5.2.3.2 Integration with telehealth and digital health platforms 63
5.2.3.3 Increased number of collaborations and partnerships among healthcare organizations 64
5.2.3.4 Increasing number of government initiatives and policies toward genetic health improvement 64
5.2.3.5 Growing focus on health screening for rare diseases 65
5.2.4 CHALLENGES 65
5.2.4.1 Lack of skilled professionals 65
5.2.4.2 Lack of standard guidelines for carrier screening 65
5.3 TRENDS 66
5.3.1 LACK OF PUBLIC INTEREST IN EXPANDED CARRIER SCREENING 66
5.4 PRICING ANALYSIS 66
TABLE 4 INDICATIVE PRICING OF CARRIER SCREENING PRODUCTS/SERVICES 66
TABLE 5 AVERAGE SELLING PRICE OF PREIMPLANTATION GENETIC TESTING SYSTEMS 67
5.5 VALUE CHAIN ANALYSIS 67
FIGURE 23 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 67
5.6 SUPPLY CHAIN ANALYSIS 68
FIGURE 24 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES 69
5.7 PORTER’S FIVE FORCES ANALYSIS 69
TABLE 6 PORTER’S FIVE FORCES: CARRIER SCREENING MARKET 69
5.7.1 THREAT OF NEW ENTRANTS 69
5.7.2 THREAT OF SUBSTITUTES 70
5.7.3 BARGAINING POWER OF SUPPLIERS 70
5.7.4 BARGAINING POWER OF BUYERS 70
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 70
5.8 ECOSYSTEM/MARKET MAP 71
FIGURE 25 ECOSYSTEM/MARKET MAP: CARRIER SCREENING MARKET 71
TABLE 7 ROLE IN ECOSYSTEM: CARRIER SCREENING MARKET 71
FIGURE 26 KEY PLAYERS IN CARRIER SCREENING MARKET 72
5.9 TARIFF & REGULATORY LANDSCAPE 72
TABLE 8 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING CARRIER SCREENING MARKET 72
5.9.1 NORTH AMERICA 73
5.9.1.1 US 73
5.9.1.2 Canada 73
5.9.2 EUROPE 73
5.9.2.1 UK 73
5.9.2.2 France 73
5.9.3 ASIA PACIFIC 74
5.9.3.1 Japan 74
5.9.3.2 India 74
5.10 PATENT ANALYSIS 74
5.10.1 PATENT TRENDS FOR CARRIER SCREENING 74
FIGURE 27 PATENT TRENDS FOR CARRIER SCREENING, JANUARY 2013–DECEMBER 2023 74
5.10.2 JURISDICTION AND TOP APPLICANT ANALYSIS 75
FIGURE 28 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR CARRIER SCREENING PATENTS, JANUARY 2013– DECEMBER 2023 75
5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 75
5.11.1 REVENUE SHIFT AND REVENUE POCKETS FOR CARRIER SCREENING MANUFACTURERS 75
FIGURE 29 REVENUE SHIFT FOR CARRIER SCREENING PRODUCTS/SERVICES 76
5.12 KEY CONFERENCES & EVENTS 76
TABLE 9 DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2024–DECEMBER 2025 76
5.13 TECHNOLOGY ANALYSIS 77
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 78
5.14.1 KEY STAKEHOLDERS 78
FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CARRIER SCREENING PRODUCTS 78
TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CARRIER SCREENING PRODUCTS (%) 78
5.14.2 BUYING CRITERIA 78
FIGURE 31 KEY BUYING CRITERIA FOR END USERS OF CARRIER SCREENING PRODUCTS/SERVICES 78
TABLE 11 KEY BUYING CRITERIA FOR END USERS OF CARRIER SCREENING PRODUCTS/SERVICES 79
5.15 TRADE ANALYSIS 79
TABLE 12 IMPORT DATA FOR HS CODE 901849, BY COUNTRY, 2018–2022 (USD MILLION) 79
TABLE 13 EXPORT DATA FOR HS CODE 901849, BY COUNTRY, 2018–2022 (USD MILLION) 79
6 CARRIER SCREENING MARKET, BY PRODUCT & SERVICE 80
6.1 INTRODUCTION 81
TABLE 14 CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 81
6.2 SERVICES 81
6.2.1 RISING NUMBER OF ACCREDITED LABORATORIES AND GENETIC CASES TO DRIVE MARKET 81
TABLE 15 CARRIER SCREENING MARKET FOR SERVICES, BY REGION, 2021–2028 (USD MILLION) 82
6.3 PRODUCTS 82
6.3.1 GROWING INCIDENCE OF CHROMOSOMAL ABNORMALITIES AND RISING USE OF CARRIER SCREENING TESTS TO DRIVE MARKET 82
TABLE 16 KEY PLAYERS PROVIDING CARRIER SCREENING PRODUCTS 83
TABLE 17 CARRIER SCREENING MARKET FOR PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 83
7 CARRIER SCREENING MARKET, BY TYPE 84
7.1 INTRODUCTION 85
TABLE 18 CARRIER SCREENING MARKET, BY TYPE, 2021–2028 (USD MILLION) 85
7.2 EXPANDED CARRIER SCREENING 85
TABLE 19 CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION) 86
TABLE 20 CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY REGION, 2021–2028 (USD MILLION) 86
7.2.1 PREDESIGNED PANEL TESTING 86
7.2.1.1 Predesigned panel testing segment to command larger market share during forecast period 86
TABLE 21 PREDESIGNED PANEL TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 88
7.2.2 CUSTOMIZED PANEL TESTING 88
7.2.2.1 Better customization options for meeting specific customer requirements to drive segment 88
TABLE 22 CUSTOMIZED PANEL TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 88
7.3 TARGETED DISEASE CARRIER SCREENING 89
7.3.1 INTRODUCTION OF PANELS FOR SIMULTANEOUSLY SCREENING MULTIPLE GENETIC CONDITIONS TO DRIVE MARKET 89
TABLE 23 CARRIER SCREENING MARKET FOR TARGETED DISEASE CARRIER SCREENING, BY REGION, 2021–2028 (USD MILLION) 89
8 CARRIER SCREENING MARKET, BY MEDICAL CONDITION 90
8.1 INTRODUCTION 91
TABLE 24 CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION) 91
8.2 PULMONARY CONDITIONS 91
8.2.1 INCREASING AWARENESS ABOUT CYSTIC FIBROSIS IN REPRODUCTIVE PLANNING TO DRIVE MARKET 91
TABLE 25 LIVE BIRTH INCIDENCE OF CYSTIC FIBROSIS 92
TABLE 26 CARRIER SCREENING PRODUCTS/SERVICES FOR CYSTIC FIBROSIS 92
TABLE 27 CARRIER SCREENING MARKET FOR PULMONARY CONDITIONS, BY REGION, 2021–2028 (USD MILLION) 93
8.3 HEMATOLOGICAL CONDITIONS 93
8.3.1 RISING PREVALENCE OF HEMATOLOGICAL DISORDERS AMONG INFANTS TO DRIVE MARKET 93
TABLE 28 CARRIER SCREENING MARKET FOR HEMATOLOGICAL CONDITIONS, BY REGION, 2021–2028 (USD MILLION) 94
8.4 NEUROLOGICAL CONDITIONS 94
8.4.1 INCREASED AWARENESS OF NEUROLOGICAL SCREENING AND PRESENCE OF TARGETED SCREENING PANELS TO DRIVE MARKET 94
TABLE 29 GLOBAL PREVALENCE OF NEUROLOGICAL CONDITIONS 95
TABLE 30 CARRIER SCREENING PRODUCTS/SERVICES FOR NEUROLOGICAL CONDITIONS 95
TABLE 31 CARRIER SCREENING MARKET FOR NEUROLOGICAL CONDITIONS, BY REGION, 2021–2028 (USD MILLION) 96
8.5 OTHER MEDICAL CONDITIONS 96
TABLE 32 CARRIER SCREENING MARKET FOR OTHER MEDICAL CONDITIONS, BY REGION, 2021–2028 (USD MILLION) 97
9 CARRIER SCREENING MARKET, BY TECHNOLOGY 98
9.1 INTRODUCTION 99
TABLE 33 CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 99
9.2 DNA SEQUENCING 99
9.2.1 DNA SEQUENCING SEGMENT TO DOMINATE MARKET DURING STUDY PERIOD 99
TABLE 34 DNA SEQUENCING USED BY MARKET PLAYERS 100
TABLE 35 CARRIER SCREENING MARKET FOR DNA SEQUENCING, BY REGION, 2021–2028 (USD MILLION) 100
9.3 PCR 101
9.3.1 HIGH ACCURACY, LOW REACTION TIME, AND ABSOLUTE ESTIMATION OF TARGET MOLECULE TO DRIVE MARKET 101
TABLE 36 PCR USED BY MARKET PLAYERS 101
TABLE 37 CARRIER SCREENING MARKET FOR PCR, BY REGION, 2021–2028 (USD MILLION) 101
9.4 DNA MICROARRAYS 102
9.4.1 ABILITY TO ANALYZE MULTIPLE GENETIC MARKERS IN SINGLE ASSAY TO DRIVE MARKET 102
TABLE 38 DNA MICROARRAYS USED BY MARKET PLAYERS 102
TABLE 39 CARRIER SCREENING MARKET FOR DNA MICROARRAYS, BY REGION, 2021–2028 (USD MILLION) 102
9.5 OTHER TECHNOLOGIES 103
TABLE 40 ADVANTAGES OF OTHER TECHNOLOGIES FOR CARRIER SCREENING 103
TABLE 41 CARRIER SCREENING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION) 103
10 CARRIER SCREENING MARKET, BY END USER 104
10.1 INTRODUCTION 105
TABLE 42 CARRIER SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 105
10.2 HOSPITALS AND MEDICAL CENTERS 105
10.2.1 RISING PATIENT POPULATION AND INCREASING MEDICARE REIMBURSEMENT FOR CLINICAL TESTS TO DRIVE SEGMENT 105
TABLE 43 CARRIER SCREENING MARKET FOR HOSPITALS AND MEDICAL CENTERS, BY REGION, 2021–2028 (USD MILLION) 106
10.3 CLINICAL LABORATORIES 106
10.3.1 LOWER SERVICE COSTS AND HIGHER TURNAROUND TIME TO DRIVE MARKET 106
TABLE 44 CARRIER SCREENING MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 107
10.4 FERTILITY CLINICS 107
10.4.1 INCREASING NUMBER OF INFERTILE COUPLES AND GROWING MEDICAL TOURISM IN EMERGING ECONOMIES TO DRIVE MARKET 107
TABLE 45 CARRIER SCREENING MARKET FOR FERTILITY CLINICS, BY REGION, 2021–2028 (USD MILLION) 108
10.5 OTHER END USERS 108
TABLE 46 CARRIER SCREENING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 109
11 CARRIER SCREENING MARKET, BY REGION 110
11.1 INTRODUCTION 111
TABLE 47 CARRIER SCREENING MARKET, BY REGION, 2021–2028 (USD MILLION) 111
11.2 NORTH AMERICA 111
FIGURE 32 NORTH AMERICA: CARRIER SCREENING MARKET SNAPSHOT 112
TABLE 48 NORTH AMERICA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 113
TABLE 49 NORTH AMERICA: CARRIER SCREENING MARKET, BY TYPE, 2021–2028 (USD MILLION) 113
TABLE 50 NORTH AMERICA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION) 113
TABLE 51 NORTH AMERICA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 114
TABLE 52 NORTH AMERICA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION) 114
TABLE 53 NORTH AMERICA: CARRIER SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 115
TABLE 54 NORTH AMERICA: CARRIER SCREENING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 115
11.2.1 NORTH AMERICA: RECESSION IMPACT 115
11.2.2 US 116
11.2.2.1 Increasing number of genetic diseases and rising healthcare expenditure to drive market 116
TABLE 55 US: KEY MACROINDICATORS 117
TABLE 56 US: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 117
TABLE 57 US: CARRIER SCREENING MARKET, BY TYPE, 2021–2028 (USD MILLION) 118
TABLE 58 US: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION) 118
TABLE 59 US: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 118
TABLE 60 US: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION) 119
TABLE 61 US: CARRIER SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 119
11.2.3 CANADA 119
11.2.3.1 Increasing government and non-government funding to drive market 119
TABLE 62 CANADA: KEY MACROINDICATORS 120
TABLE 63 CANADA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 121
TABLE 64 CANADA: CARRIER SCREENING MARKET, BY TYPE, 2021–2028 (USD MILLION) 121
TABLE 65 CANADA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION) 121
TABLE 66 CANADA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 122
TABLE 67 CANADA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION) 122
TABLE 68 CANADA: CARRIER SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 122
11.3 EUROPE 123
TABLE 69 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY (% OF GDP) 123
11.3.1 EUROPE: RECESSION IMPACT 124
TABLE 70 EUROPE: CARRIER SCREENING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 71 EUROPE: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 125
TABLE 72 EUROPE: CARRIER SCREENING MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 73 EUROPE: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 74 EUROPE: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 126
TABLE 75 EUROPE: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION) 126
TABLE 76 EUROPE: CARRIER SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 126
11.3.2 GERMANY 127
11.3.2.1 Increasing number of government initiatives and healthcare expenditures to drive market 127
TABLE 77 GERMANY: KEY MACROINDICATORS 128
TABLE 78 GERMANY: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 128
TABLE 79 GERMANY: CARRIER SCREENING MARKET, BY TYPE, 2021–2028 (USD MILLION) 128
TABLE 80 GERMANY: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 81 GERMANY: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 129
TABLE 82 GERMANY: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION) 129
TABLE 83 GERMANY: CARRIER SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 130
11.3.3 UK 130
11.3.3.1 Rising prevalence of hematological disease and increasing number of accredited clinical laboratories to drive market 130
TABLE 84 UK: KEY MACROINDICATORS 131
TABLE 85 UK: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 131
TABLE 86 UK: CARRIER SCREENING MARKET, BY TYPE, 2021–2028 (USD MILLION) 131
TABLE 87 UK: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 88 UK: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 132
TABLE 89 UK: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION) 132
TABLE 90 UK: CARRIER SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 133
11.3.4 FRANCE 133
11.3.4.1 Better healthcare infrastructure and higher expenditure for life science research to drive market 133
TABLE 91 FRANCE: KEY MACROINDICATORS 134
TABLE 92 FRANCE: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 134
TABLE 93 FRANCE: CARRIER SCREENING MARKET, BY TYPE, 2021–2028 (USD MILLION) 134
TABLE 94 FRANCE: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 95 FRANCE: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 135
TABLE 96 FRANCE: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION) 135
TABLE 97 FRANCE: CARRIER SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 136
11.3.5 ITALY 136
11.3.5.1 Growing prevalence of chronic diseases and rising number of hospitals to drive market 136
TABLE 98 ITALY: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 137
TABLE 99 ITALY: CARRIER SCREENING MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 100 ITALY: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 101 ITALY: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 138
TABLE 102 ITALY: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION) 138
TABLE 103 ITALY: CARRIER SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 138
11.3.6 SPAIN 139
11.3.6.1 Increasing prevalence of rare genetic diseases and rising availability of research funding to drive market 139
TABLE 104 SPAIN: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 139
TABLE 105 SPAIN: CARRIER SCREENING MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 106 SPAIN: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 107 SPAIN: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 140
TABLE 108 SPAIN: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION) 141
TABLE 109 SPAIN: CARRIER SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 141
11.3.7 REST OF EUROPE 141
TABLE 110 REST OF EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2021 (% OF GDP) 142
TABLE 111 REST OF EUROPE: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 142
TABLE 112 REST OF EUROPE: CARRIER SCREENING MARKET, BY TYPE, 2021–2028 (USD MILLION) 142
TABLE 113 REST OF EUROPE: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 114 REST OF EUROPE: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 143
TABLE 115 REST OF EUROPE: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION) 143
TABLE 116 REST OF EUROPE: CARRIER SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 144
11.4 ASIA PACIFIC 144
11.4.1 ASIA PACIFIC: RECESSION IMPACT 145
FIGURE 33 ASIA PACIFIC: CARRIER SCREENING MARKET SNAPSHOT 146
TABLE 117 ASIA PACIFIC: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 146
TABLE 118 ASIA PACIFIC: CARRIER SCREENING MARKET, BY TYPE, 2021–2028 (USD MILLION) 147
TABLE 119 ASIA PACIFIC: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION) 147
TABLE 120 ASIA PACIFIC: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 147
TABLE 121 ASIA PACIFIC: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION) 148
TABLE 122 ASIA PACIFIC: CARRIER SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 148
11.4.2 INDIA 148
11.4.2.1 Growing incidence of rare diseases and declining fertility rates to drive market 148
TABLE 123 INDIA: KEY MACROINDICATORS 149
TABLE 124 INDIA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 149
TABLE 125 INDIA: CARRIER SCREENING MARKET, BY TYPE, 2021–2028 (USD MILLION) 150
TABLE 126 INDIA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION) 150
TABLE 127 INDIA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 150
TABLE 128 INDIA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION) 151
TABLE 129 INDIA: CARRIER SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 151
11.4.3 CHINA 151
11.4.3.1 Rising focus on vaccine development and cancer research to drive market 151
TABLE 130 CHINA: KEY MACROINDICATORS 152
TABLE 131 CHINA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 152
TABLE 132 CHINA: CARRIER SCREENING MARKET, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 133 CHINA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 134 CHINA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 153
TABLE 135 CHINA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION) 154
TABLE 136 CHINA: CARRIER SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 154
11.4.4 JAPAN 154
11.4.4.1 Rising geriatric population and growing government healthcare expenditure to drive market 154
TABLE 137 JAPAN: KEY MACROINDICATORS 155
TABLE 138 JAPAN: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 156
TABLE 139 JAPAN: CARRIER SCREENING MARKET, BY TYPE, 2021–2028 (USD MILLION) 156
TABLE 140 JAPAN: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION) 156
TABLE 141 JAPAN: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 157
TABLE 142 JAPAN: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION) 157
TABLE 143 JAPAN: CARRIER SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 157
11.4.5 REST OF ASIA PACIFIC 158
TABLE 144 REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 159
TABLE 145 REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY TYPE, 2021–2028 (USD MILLION) 159
TABLE 146 REST OF ASIA PACIFIC: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION) 159
TABLE 147 REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 160
TABLE 148 REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION) 160
TABLE 149 REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 161
11.5 REST OF THE WORLD 161
11.5.1 REST OF THE WORLD: RECESSION IMPACT 162
TABLE 150 REST OF THE WORLD: CARRIER SCREENING MARKET, BY PRODUCT & 2021–2028 (USD MILLION) 162
TABLE 151 REST OF THE WORLD: CARRIER SCREENING MARKET, BY TYPE, 2021–2028 (USD MILLION) 162
TABLE 152 REST OF THE WORLD: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION) 163
TABLE 153 REST OF THE WORLD: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 163
TABLE 154 REST OF THE WORLD: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION) 163
TABLE 155 REST OF THE WORLD: CARRIER SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 164
11.5.2 LATIN AMERICA 164
11.5.2.1 Higher prevalence of genetic disorders and growing focus on reproductive healthcare services to drive market 164
TABLE 156 DEFINITION OF RARE DISEASES IN VARIOUS COUNTRIES 164
TABLE 157 LATIN AMERICA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 165
TABLE 158 LATIN AMERICA: CARRIER SCREENING MARKET, BY TYPE, 2021–2028 (USD MILLION) 165
TABLE 159 LATIN AMERICA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 160 LATIN AMERICA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 166
TABLE 161 LATIN AMERICA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION) 166
TABLE 162 LATIN AMERICA: CARRIER SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 167
11.5.3 MIDDLE EAST & AFRICA 167
TABLE 163 MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 168
TABLE 164 MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY TYPE, 2021–2028 (USD MILLION) 168
TABLE 165 MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION) 168
TABLE 166 MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 169
TABLE 167 MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION) 169
TABLE 168 MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 170
11.5.3.1 GCC Countries 170
11.5.3.1.1 Improved healthcare infrastructure and launch of genome projects to drive market 170
TABLE 169 GCC COUNTRIES: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 171
TABLE 170 GCC COUNTRIES: CARRIER SCREENING MARKET, BY TYPE, 2021–2028 (USD MILLION) 171
TABLE 171 GCC COUNTRIES: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 172 GCC COUNTRIES: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 172
TABLE 173 GCC COUNTRIES: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021–2028 (USD MILLION) 172
TABLE 174 GCC COUNTRIES: CARRIER SCREENING MARKET, BY END USER, 2021–2028 (USD MILLION) 173
12 COMPETITIVE LANDSCAPE 174
12.1 OVERVIEW 174
12.2 KEY STRATEGIES/RIGHT TO WIN 174
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 174
TABLE 175 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CARRIER SCREENING MARKET 174
12.3 MARKET SHARE ANALYSIS 175
TABLE 176 DEGREE OF COMPETITION: CARRIER SCREENING MARKET 175
12.4 REVENUE SHARE ANALYSIS 175
FIGURE 34 REVENUE SHARE ANALYSIS OF KEY PLAYERS 176
12.5 COMPANY EVALUATION MATRIX 177
12.5.1 STARS 177
12.5.2 EMERGING LEADERS 177
12.5.3 PERVASIVE PLAYERS 177
12.5.4 PARTICIPANTS 177
FIGURE 35 COMPANY EVALUATION MATRIX, 2022 178
12.5.5 COMPANY FOOTPRINT 178
TABLE 177 OVERALL COMPANY FOOTPRINT 178
TABLE 178 PRODUCT FOOTPRINT 179
TABLE 179 REGIONAL FOOTPRINT 180
12.6 START-UP/SME EVALUATION MATRIX 181
12.6.1 PROGRESSIVE COMPANIES 181
12.6.2 RESPONSIVE COMPANIES 181
12.6.3 DYNAMIC COMPANIES 181
12.6.4 STARTING BLOCKS 182
FIGURE 36 START-UP/SME EVALUATION MATRIX, 2022 182
12.6.5 COMPETITIVE BENCHMARKING 182
TABLE 180 DETAILED LIST OF KEY START-UPS/SMES IN CARRIER SCREENING MARKET 182
12.7 COMPETITIVE SCENARIOS AND TRENDS 183
12.7.1 KEY DEALS 183
TABLE 181 KEY DEALS, JANUARY 2020–DECEMBER 2023 183
13 COMPANY PROFILES 184
13.1 KEY PLAYERS 184
(Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and Competitive threats)*
13.1.1 NATERA, INC. 184
TABLE 182 NATERA, INC.: COMPANY OVERVIEW 184
FIGURE 37 NATERA, INC.: COMPANY SNAPSHOT (2022) 185
13.1.2 QUEST DIAGNOSTICS INCORPORATED 187
TABLE 183 QUEST DIAGNOSTICS INCORPORATED: COMPANY OVERVIEW 187
FIGURE 38 QUEST DIAGNOSTICS INCORPORATED: COMPANY SNAPSHOT (2022) 187
13.1.3 FULGENT GENETICS 189
TABLE 184 FULGENT GENETICS: COMPANY OVERVIEW 189
FIGURE 39 FULGENT GENETICS.: COMPANY SNAPSHOT (2022) 190
13.1.4 INVITAE CORPORATION 192
TABLE 185 INVITAE CORPORATION: COMPANY OVERVIEW 192
FIGURE 40 INVITAE CORPORATION.: COMPANY SNAPSHOT (2022) 193
13.1.5 EUROFINS SCIENTIFIC 195
TABLE 186 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 195
FIGURE 41 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022) 195
13.1.6 OPKO HEALTH, INC. 197
TABLE 187 OPKO HEALTH, INC.: COMPANY OVERVIEW 197
FIGURE 42 OPKO HEALTH, INC.: COMPANY SNAPSHOT (2022) 198
13.1.7 THERMO FISHER SCIENTIFIC INC. 200
TABLE 188 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 200
FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 201
13.1.8 MYRIAD GENETICS, INC. 202
TABLE 189 MYRIAD GENETICS, INC.: COMPANY OVERVIEW 202
FIGURE 44 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2022) 203
13.1.9 ILLUMINA, INC. 204
TABLE 190 ILLUMINA, INC.: COMPANY OVERVIEW 204
FIGURE 45 ILLUMINA, INC.: COMPANY SNAPSHOT (2022) 205
13.1.10 LABORATORY CORPORATION OF AMERICA HOLDINGS 206
TABLE 191 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW 206
FIGURE 46 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022) 207
13.1.11 CENTOGENE N.V. 209
TABLE 192 CENTOGENE N.V.: COMPANY OVERVIEW 209
FIGURE 47 CENTOGENE N.V.: COMPANY SNAPSHOT (2022) 210
13.1.12 DIASORIN S.P.A. 211
TABLE 193 DIASORIN S.P.A.: COMPANY OVERVIEW 211
FIGURE 48 DIASORIN S.P.A.: COMPANY SNAPSHOT (2023) 212
13.1.13 BGI 213
TABLE 194 BGI: COMPANY OVERVIEW 213
13.1.14 OTOGENETICS 214
TABLE 195 OTOGENETICS: COMPANY OVERVIEW 214
13.1.15 GENETECH 215
TABLE 196 GENETECH: COMPANY OVERVIEW 215
13.2 OTHER PLAYERS 216
13.2.1 OXY-GEN LABORATORY LLC 216
TABLE 197 OXY-GEN LABORATORY LLC: COMPANY OVERVIEW 216
13.2.2 MEDGENOME 217
TABLE 198 MEDGENOME: COMPANY OVERVIEW 217
13.2.3 AMBRY GENETICS. 218
TABLE 199 AMBRY GENETICS: COMPANY OVERVIEW 218
13.2.4 ASPER BIOGENE 219
TABLE 200 ASPER BIOGENE: COMPANY OVERVIEW 219
13.2.5 LIFELABS GENETICS 220
TABLE 201 LIFELABS GENETICS: COMPANY OVERVIEW 220
13.2.6 EASYDNA 221
TABLE 202 EASYDNA: COMPANY OVERVIEW 221
13.2.7 LIFECELL 222
TABLE 203 LIFECELL: COMPANY OVERVIEW 222
13.2.8 CNC PATH LAB 223
TABLE 204 CNC PATH LAB: COMPANY OVERVIEW 223
13.2.9 SIGNATURE DIAGNOSTICS INC. 224
TABLE 205 SIGNATURE DIAGNOSTICS INC.: COMPANY OVERVIEW 224
13.2.10 MITERA 225
TABLE 206 MITERA: COMPANY OVERVIEW 225
*Details on Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.
14 APPENDIX 226
14.1 DISCUSSION GUIDE 226
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 229
14.3 CUSTOMIZATION OPTIONS 231
14.4 RELATED REPORTS 231
14.5 AUTHOR DETAILS 232